| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
¶
From the Department of Pathology and Laboratory Medicine,* Department of Pediatrics,¶ Jonsson Comprehensive Cancer Center, and Molecular Biology Institute, University of California at Los Angeles School of Medicine, Los Angeles; and the Department of Dermatology, University of California at Davis School of Medicine, Davis, California
Increased resistance to apoptosis promotes lymphomagenesis with aberrant expression of cell survival proteins such as BCL-2 and c-MYC occurring in distinct lymphoma subtypes. Galectin-3 is an anti-apoptotic protein that protects T cells, macrophages, and breast carcinoma cells from death triggered by a variety of agents. We have found high levels of galectin-3 protein expression in a subset of B-cell neoplasms including diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma (PEL), and multiple myeloma (MM), in both cell lines and patient samples. However, we failed to detect galectin-3 in Burkitt lymphoma (BL), follicular lymphoma (FL), marginal zone lymphoma (MZL), MALT lymphoma or B-small lymphocytic lymphoma (B-SLL) cell lines or patient samples. To determine whether galectin-3 expression protects B cells from apoptosis, galectin-3-negative BL cells were transfected with a galectin-3 expressing plasmid, which resulted in markedly increased resistance to anti-Fas-induced cell death. In contrast, galectin-3-positive PEL cells transfected with an amino-terminal truncated galectin-3 vector showed increased sensitivity to anti-Fas induced apoptosis. During normal B-cell development, galectin-3 expression was lowest in germinal center and plasma B cells, from which DLBCL, PEL, and MM derive, and highest in long-lived naïve and memory B cells. This pattern of expression suggests that aberrantly increased galectin-3 levels in specific B-cell populations may yield a protective advantage during transformation and/or progression of certain B-cell neoplasms.
This article has been cited by other articles:
 |
|
 |
|
  C. Saravanan, F.-T. Liu, I. K. Gipson, and N. Panjwani Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on {alpha}3{beta}1 integrin J. Cell Sci., October 15, 2009; 122(20): 3684 - 3693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Oliveira, P. Frazao, R. Chammas, D. K. Hsu, F. T. Liu, R. Borojevic, C. M. Takiya, and M. C. El-Cheikh Kinetics of mobilization and differentiation of lymphohematopoietic cells during experimental murine schistosomiasis in galectin-3 / mice J. Leukoc. Biol., August 1, 2007; 82(2): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yu, R. Siegel, and R. G. Roeder Interaction of the B Cell-specific Transcriptional Coactivator OCA-B and Galectin-1 and a Possible Role in Regulating BCR-mediated B Cell Proliferation J. Biol. Chem., June 2, 2006; 281(22): 15505 - 15516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Rabinovich, A. Cumashi, G. A. Bianco, D. Ciavardelli, I. Iurisci, M. D'Egidio, E. Piccolo, N. Tinari, N. Nifantiev, and S. Iacobelli Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis Glycobiology, March 1, 2006; 16(3): 210 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Stillman, D. K. Hsu, M. Pang, C. F. Brewer, P. Johnson, F.-T. Liu, and L. G. Baum Galectin-3 and Galectin-1 Bind Distinct Cell Surface Glycoprotein Receptors to Induce T Cell Death J. Immunol., January 15, 2006; 176(2): 778 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J M Ilarregui, G A Bianco, M A Toscano, and G A Rabinovich The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv96 - iv103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chauhan, G. Li, K. Podar, T. Hideshima, P. Neri, D. He, N. Mitsiades, P. Richardson, Y. Chang, J. Schindler, et al. A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells Cancer Res., September 15, 2005; 65(18): 8350 - 8358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Fernandez, J. M. Ilarregui, C. J. Rubel, M. A. Toscano, S. A. Gomez, M. Beigier Bompadre, M. A. Isturiz, G. A. Rabinovich, and M. S. Palermo Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways Glycobiology, May 1, 2005; 15(5): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
